Acerus Pharmaceuticals Co. (TSE:ASP)’s share price reached a new 52-week low on Friday . The stock traded as low as C$0.20 and last traded at C$0.20, with a volume of 147038 shares. The stock had previously closed at C$0.21.
The company has a debt-to-equity ratio of 81.16, a current ratio of 1.01 and a quick ratio of 0.72.
Acerus Pharmaceuticals (TSE:ASP) last released its quarterly earnings results on Friday, August 10th. The company reported C($0.04) earnings per share for the quarter, hitting the consensus estimate of C($0.04). The company had revenue of C$2.71 million for the quarter, compared to analysts’ expectations of C$2.51 million. Sell-side analysts anticipate that Acerus Pharmaceuticals Co. will post -0.02 EPS for the current year.
In related news, Director Edward Joseph Gudaitis purchased 224,000 shares of the company’s stock in a transaction on Monday, August 27th. The stock was bought at an average price of C$0.28 per share, with a total value of C$62,720.00. Insiders have acquired 1,693,000 shares of company stock valued at $456,255 in the last three months.
COPYRIGHT VIOLATION WARNING: “Acerus Pharmaceuticals (ASP) Reaches New 12-Month Low at $0.20” was originally reported by Macon Daily and is owned by of Macon Daily. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://macondaily.com/2018/11/09/acerus-pharmaceuticals-asp-reaches-new-12-month-low-at-0-20.html.
Acerus Pharmaceuticals Company Profile (TSE:ASP)
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.
Further Reading: Cost of Capital
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.